The encouraging progress of the Janssen collaboration, together with the successful findings from our relationship with Roche on cell-penetrating peptides targeting the blood-brain barrier, suggest that Phylomers can be used to target specific types of cell and deliver large biological payloads across cell membranes. These conjugates have broad application in many disease areas such as cancer and other indications with a high unmet medical need.
There is enormous potential value in this area of emerging interest to the pharmaceutical industry, which is why we are evolving our discovery platform with new technologies to optimise the screening of our libraries to identify cell-specific peptides that can penetrate cell membranes.
This provides us with a further advantage over our peers in discovering and developing next-generation peptide therapeutics.
On the 20/03/13 I wrote...
I wonder whether the technology that Mark Dennis is referring to in the video (i.e., Transferrin Receptor Technology) is what Phylogica are looking to improve upon with their 2nd generation libraries?
Last night you wrote....
Genentech received international acclaim for their breakthrough in crossing the BBB. The progression of the collaboration with Phylogica highlights the significance of the BEN_5000 discovery in advancing the science. It would appear that the bispecific antibody is already being superceded.
I agree Wayne, it appears that the 'successful findings' that Phylogica highlighted within the newsletter may actually refer to the company's 2nd generation libraries as superceding their technology.
This Patent is another significant step for Phylogica. This patent will certainly cover the second generation libraries and it's very broad. :-)
Regards, Tony
PYC Price at posting:
2.3¢ Sentiment: LT Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)